Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06091995 · ClinicalTrials.gov registry record
Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients with Delayed Graft Function
A clinical trial of Use of Belatacept in Kidney Transplant Patients, sponsored by Methodist Health System.
- Active
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06091995: Active study of Use of Belatacept in Kidney Transplant Patients, sponsored by Methodist Health System.
NCT06091995 is a study of Use of Belatacept in Kidney Transplant Patients that is active but no longer recruiting, run by Methodist Health System. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06091995, a study of Use of Belatacept in Kidney Transplant Patients, is active but no longer recruiting, sponsored by Methodist Health System.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.
Primary Outcome
weeks 1-4, and months 3, 6, 9 and 12) to capture potential short- and long-term effects on renal function.
Conditions Studied
Interventions
- BEHAVIORAL impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2025-08-22 |
What the registry record for NCT06091995 still lists
NCT06091995 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Use of Belatacept in Kidney Transplant Patients appearing as the primary indexed condition, and to 1 intervention - of which impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR) is the first listed.
NCT06091995 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06091995 about?
NCT06091995 is a clinical study titled "Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients with Delayed Graft Function". Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.
What is the current status of trial NCT06091995?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2022-08-22. Estimated completion is 2025-08-22.
What conditions does trial NCT06091995 study?
This clinical trial studies the following conditions: Use of Belatacept in Kidney Transplant Patients.
What interventions are being tested in trial NCT06091995?
The interventions under investigation include: impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06091995?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06091995 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI